IDE196

Drug identity checked against registry records

Also recorded as Darovasertib

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332IDEAYA BiosciencesPhase 2, Phase 3Active not recruiting2027-01-15Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.